PRKG2 inhibits the migration, invasion, and proliferation of cancer cells and activates CREB, which modulates anti-apoptotic genes, such as BCL2 (Shankar et al., 2010), which are overexpressed in the resistant group, thereby contributing to the survival of cancer cells in the resistant group. The gene discussed is BCL2; the disease is cancer.